The Life Sciences Report
Other Streetwise Reports
The Gold Report The Energy Report The Life Sciences Report The Metals ReportMore Experts
"The Abstral acquisition has transformed GALE from a development biotech company into a commercial organization." (4/4/13) Galena Biopharma Inc. - The Life Sciences Report Interview with Grant Zeng More >
"I believe the monoclonal antibody technology that SYN is working on for pertussis is especially interesting." (3/28/13) Synthetic Biologics Inc. - The Life Sciences Report Interview with Keith Markey More >
"ATHX has one of the best manufacturing processes in allogeneic cell therapy I've ever seen." (3/14/13) Athersys Inc. - The Life Sciences Report Interview with Jason Kolbert More >
"If phase 2b ASSURE trial results show a significant decrease in atherosclerotic plaque volume, it will be a huge win for RVX." (3/7/13) Resverlogix Corp. - The Life Sciences Report Interview with George Zavoico More >
"It is very rare to see a $60M market cap company with all the positive attributes LPTN has." (2/14/13) Lpath Inc. - The Life Sciences Report interview with Ram Selvaraju More >
Sector Experts
Subscribe to
Streetwise Reports
Companies Commented On
- BG Medicine
- Exact Sciences Corp.
- Genetic Sciences
- Genetic Technologies Ltd.
- Genomic Health Inc.
- Myriad Genetics Inc.
- Navidea Biopharmaceuticals Inc.
- NeoGenomics Laboratories
- OPKO Health Inc.
- Response Genetics
- Sequenom Inc.
- Vermillion, Inc.
Kevin DeGeeter
Kevin DeGeeter is a director at Ladenburg Thalmann & Co. Inc. He is responsible for equity research coverage of personalized medicine and medical device companies with market capitalizations between $50 million and $5 billion. His coverage focuses on molecular diagnostics and medical equipment used to treat oncology, cardiovascular disease and infectious disease, as well as related research markets. Prior to joining Ladenburg Thalmann he was an analyst at Oppenheimer & Co., with responsibility for small-cap molecular diagnostic and biotechnology stocks. He has 10 years of buyside and sellside research experience, including positions with J. P. Morgan, PaineWebber, Natexis Bleichroeder and Manning & Napier Advisors. DeGeeter received a bachelor's degree in economics from Colgate University.
Recent Interviews
Testing, Testing: Analyst Kevin DeGeeter on Five Good Bets in Cancer Diagnostics (11/29/12) Because margins in diagnostics and life sciences tools tend to decline over time, the industry is all about scale. The goal is either to develop novel products or tests with high profit potential, or to acquire them. Another strategy is to develop economies of scale through consolidation. In this interview with The Life Sciences Report, Kevin DeGeeter, senior analyst and director of healthcare research for Ladenburg Thalmann, has singled out five important companies with exciting business models or products.
Will Mayo v. Prometheus Fire Up Pharma?: Kevin DeGeeter (5/10/12) Newly discovered biomarkers could provide physicians with information that will aid in the diagnosis and treatment of disease. The big question for investors is whether, in light of the recent Supreme Court ruling Mayo Collaborative Services Inc. v. Prometheus Laboratories, companies will be able to profit from that innovation. In this exclusive interview with The Life Sciences Report, Kevin DeGeeter, senior analyst with Ladenburg Thalmann & Co. Inc., shares the names of a select group of companies with good prospects, focusing on those targeting "sweet spots" in personalized medicine.
Recent Quotes
"OPK's prostate test remains a source for potential upside." (3/19/13) OPKO Health Inc. - Kevin DeGeeter, Ladenburg Thalmann More >
"NEO grew test volumes 35.3% in Q4/12, which suggests it continues to gain market share." (2/14/13) NeoGenomics Laboratories - Kevin DeGeeter, Ladenburg Thalmann More >
"Consolidation in molecular testing providers is a potential positive for strong operators such as NEO." (2/5/13) NeoGenomics Laboratories - Kevin DeGeeter, Ladenburg Thalmann More >
"OPK's diagnostic programs could be novel and bring unique value." (11/29/12) OPKO Health Inc. - The Life Sciences Report Interview with Kevin DeGeeter More >
"NGNM has an extremely attractive business model; I'm rating it a Buy." (11/29/12) NeoGenomics Laboratories - The Life Sciences Report Interview with Kevin DeGeeter More >
"NGNM is well positioned to be among the leaders in the market." (11/14/12) NeoGenomics Laboratories - Kevin DeGeeter, Ladenburg Thalmann More >
"Closing of the OURLab urology testing acquisition will be a transformational event for OPK." (11/12/12) OPKO Health Inc. - Kevin DeGeeter, Ladenburg Thalmann More >
"OK's acquisition generates meaningful positive cash flow and will reduce 2013's cash-burn rate." (10/22/12) OPKO Health Inc. - Kevin DeGeeter, Ladenburg Thalmann More >
Notable Quotes
"BTI's Transcend platform is a huge financial incentive to the owner of the therapy because it could greatly extend the drug's exclusivity." (5/16/13) biOasis Technologies Inc. - The Life Sciences Report Interview with William Gregozeski More >
"ATHX is a neat little company that has a great management team and deep science bench." (5/10/13) Athersys Inc. - The Life Sciences Report Interview with Jason Kolbert More >
"MSLP was growing very fast, and it had significant events that made it possible for us to raise $12M for it." (4/25/13) MusclePharm Corp. - The Life Sciences Report Interview with Richard Huebner More >
"What's particularly exciting about VNRX is that it believes its technology is able to identify targeted cancers in stage 1 and stage 2." (4/25/13) VolitionRx Ltd. - The Life Sciences Report Interview with Dick Huebner More >
"ATHX's partnership with Pfizer Inc. puts it in a remarkable position." (4/11/13) Athersys Inc. - The Life Sciences Report Interview with Steve Brozak More >